Connect with us


The EMA Outlines a Strategy for the Use of AI in the Pharmaceutical Sector

Authorities are focusing on addressing challenges related to integrating AI tools. The first initiative involves supporting AI in the life cycle of medicines. The Committee for Medicinal Products for Human Use is leading this effort. The second point aims to create a collaboration network for staying informed about new trends, leading to the establishment of an AI-focused forum by the EMA.




New plan to incorporate digital tools within the health sector. The European Medicines Agency (EMA) and the Network of Heads of Medicines Agencies (HMA) have published a document that establishes a collaborative and coordinated strategy to maximize the benefits of Artificial Intelligence (AI) within the sector.

Specifically, the objectives of the work are to take advantage of the opportunities that the new revolutionary application will have within personal productivity, the automation of processes and systems , the increase in data knowledge and more solid decision making that benefits the company. public health.

The report pointed out that national authorities are increasingly betting more on combating the challenges involved in the integration of these new tools. In fact, it recommends a strategy divided into four points that, beyond recognizing the opportunities that accompany its implementation, emphasize the challenges that it will imply for the sector.

Read more about the strategy to use AI tool in the pharmaceutical sector, and find the most important business news of the day with our companion app Born2Invest.

National authorities are increasingly betting on combating the challenges involved in the integration of AI tools

The first of them is the support of AI in the life cycle of a medicine. In this direction, both organizations point out that work has already begun through a public consultation that is open until the end of the year. In fact, they have confirmed that, by 2024, preparations will begin to support the implementation of AI law within the European Union. This work is led by a group from the Committee for Medicinal Products for Human Use (Chmp).

The second point is aimed at facilitating the development of a collaboration network that keeps the sector alert to new trends reaching the market. For this reason, the EMA has planned to create a special area of ​​interest on AI, which will result in the creation of a forum that will seek to facilitate the exchange of knowledge between different actors related to health.

The next question seeks to recognize and understand the new tools to ensure maximum efficiency , strengthening both the understanding and decision-making that your data facilitates. Regarding the new languages, the report indicates that their implementation must be staggered and monitored if their final productivity is to be guaranteed.

Finally, the plan highlights the need to experiment with new materials to ensure the acquisition of new knowledge , through cycles that will last approximately six months. After a first definition process, which will establish the main frameworks to be deployed, the different priorities will be aligned in a series of general frameworks and it will be decided which specific technical tools to adopt.


(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.